Sai Life Sciences has received the Securities and Exchange Board of India’s (SEBI's) approval to raise Rs 5,000 crore through an initial public offering (IPO). The company’s proposed IPO comprises a fresh issue of equity shares worth Rs 800 crore and an OFS of 6.15 crore shares by a promoter, investor shareholders and other shareholders.
Of the IPO proceeds, funds to the tune of Rs 600 crore will be used for debt payment and a portion will be used for corporate general purposes. Kotak Mahindra Capital Company, IIFL Securities, Jefferies India and Morgan Stanley India Company are the Book Running Lead Managers to the issue.
Sai Life Sciences provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to global pharmaceutical innovator companies and biotechnology firms.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |